Blood flow-based guidance and diagnostics using OCT

7.项目摘要/摘要 在美国，通过血流评估确诊的疾病占死亡人数的29%，是 过早发病的原因，包括造成350亿美元经济负担的视力障碍- 每年有一头狮子。对公众健康影响最大的心脏病是冠状动脉疾病 (CAD)；在美国EV进行了100多万例经皮冠状动脉介入治疗(PCI)- 每一年。在视力障碍中，糖尿病视网膜病变、黄斑变性和青光眼是主要的 在美国，ING是致盲的原因，影响着9%的40岁以上人口。所有这些疾病都被诊断为 基于使用侵入性染料造影剂技术对血流进行定性评估。 广泛的临床试验表明，根据定量血流评估指导经皮冠状动脉介入治疗 极大地改善了临床结果，但血流评估要求导管不在- 与成像导管集成在一起，增加了介入时间，从而增加了风险和成本。在- 血管光学相干断层扫描(IV-OCT)使高分辨率结构成像成为可能 并可评价经皮冠状动脉介入治疗的疗效。使血液流量量化，流量测量， 使用IV-OCT将提供功能信息，对指导治疗和改善临床至关重要 结果。同样，OCT已被确立为视网膜疾病的护理标准，提供 用于诊断的关键结构成像。众所周知，DR-MD-G的早期诊断需要具备以下功能： 以流量计的形式提供信息，检测疾病发生前血流速度的变化。 改善血管网络结构，减少相关的视力损失。 本项目开发了OCT流量测量技术平台OCT-FLOW，它依赖于对OCT-FLOW的分析。 OCT信号随机起伏的SIS及其与散射体速度场的关系10月- Flow将在基于复数幅度和基于强度的模式下提供准确的流量测量。在COM之后- 充盈，OCT-FLOW将得到充分验证，并将使CAD治疗指导和早期眼疾。 轻松诊断。OCT-FLOW的长期影响将进一步包括广泛的临床和 临床前应用，满足治疗指导和治疗对精确流量测量的巨大需求 在医疗保健方面的诊断。

7. Project Summary/Abstract Diseases diagnosed with assessment of blood flow account for 29% of deaths in the US and are leading causes of premature morbidity, including visual disorders which carry an economic burden of $35 bil- lion per year. The heart disease with the most impact on public health is coronary artery disease (CAD); more than one million percutaneous coronary interventions (PCI) are performed in the US ev- ery year. Among visual disorders diabetic retinopathy, macular degeneration and glaucoma are lead- ing causes of blindness in the US and affect 9% of the population over 40. All of these diseases are di- agnosed based on the qualitative assessment of blood flow using invasive dye contrast techniques. Extensive clinical trials have shown that guiding PCI based on quantitative blood flow assessment greatly improves the clinical outcome, but blood flow assessment requires catheters which are not in- tegrated with imaging catheters, increasing the intervention duration and therefore risk and cost. In- travascular optical coherence tomography (IV-OCT) has enabled high-resolution structural imaging of coronary arteries and can evaluate the response to PCI. Enabling blood flow quantification, flowmetry, with IV-OCT would provide functional information, critical to guide treatment and improve clinical outcomes. Similarly, OCT has been established as the standard of care in retinal diseases, providing critical structural imaging for diagnosis. It is known that early diagnosis of DR-MD-G requires func- tional information in the form of flowmetry, detecting changes in blood flow rate before the disease af- fects the vascular network structure and reducing associated vision loss. This project develops an OCT flowmetry technological platform, OCT-Flow, which relies on the analy- sis of the stochastic fluctuations of the OCT signal and its relation to the scatterers' velocity field. OCT- Flow will provide accurate flowmetry in complex-amplitude- and intensity-based modes. Upon com- pletion, OCT-Flow will be fully validated and will enable CAD treatment guidance and early eye-dis- ease diagnosis. The long-term impact of OCT-Flow will further include a wide range of clinical and preclinical applications, meeting the large demand for accurate flowmetry for treatment guidance and diagnosis in healthcare.